Modulation of the Oligomerization State of p53 by Differential Binding of Proteins of the S100 Family to p53 Monomers and Tetramers

Jan van Dieck, Maria R. Fernandez-Fernandez, Dmitry B. Veprintsev, and Alan R. Fersht

Received for publication, February 26, 2009 Published, JBC Papers in Press, March 18, 2009, DOI 10.1074/jbc.M901351200

We investigated the ways S100B, S100A1, S100A2, S100A4, and S100A6 bind to the different oligomeric forms of the tumor suppressor p53 in vitro, using analytical ultracentrifugation and multiangle light scattering. It is established that members of the S100 protein family bind to the tetramerization domain (residues 325–355) of p53 when it is uncovered in the monomer, and so binding can disrupt the tetramer. We found a stoichiometry of one dimer of S100 bound to a monomer of p53. We discovered that some S100 proteins could also bind to the tetramer. S100B bound the tetramer and also disrupted the dimer by binding monomeric p53. S100A2 bound monomeric p53 as well as tetrameric, whereas S100A1 only bound monomeric p53. S100A6 bound more tightly to tetrameric than to monomeric p53. We also identified an additional binding site for S100 proteins in the transactivation domain (1–57) of p53. Based on our results and published observations in vivo, we propose a model for the binding of S100 proteins to p53 that can explain both activation and inhibition of p53-mediated transcription. Depending on the concentration of p53 and the member of the S100 family, binding can alter the balance between monomer and tetramer in either direction.

The S100 family is a highly conserved group of more than 20 members of small, acidic calcium-binding proteins in vertebrates (1). They are called S100 because they remain soluble in 100% ammonium sulfate at neutral pH (2). S100 proteins are dimers or form higher oligomers (3, 4). They have intracellular functions such as the regulation of protein phosphorylation, the regulation of calcium homeostasis, cell survival, proliferation, and differentiation, as well as extracellular functions, for example, as attractors for leukocytes and macrophages, neurite outgrowth, or the induction of apoptosis (5–8). Further, the expression of several S100 proteins has been linked to metastasis (9) and different kinds of melanomas and carcinomas (8). Nevertheless, the molecular mechanism of action of the S100 proteins is not fully understood.

The tumor suppressor p53 is a crucial factor in the development of cancer. It acts as the central inducer of apoptosis and cell cycle arrest (10, 11). Posttranslational modifications and interaction with proteins regulate its activity (12–14). The interaction with the tumor suppressor protein p53 is a common feature of the S100 proteins (15–19). We previously demonstrated that S100 proteins generally bind to the tetramerization domain (residues 325–355) of p53, whereas only a subset can bind its negative regulatory domain (residues 367–393) (16, 20). S100B, S100A2, S100A4, and S100A6 have been reported to influence p53-mediated transcription, but the effect remains controversial because some studies show a stimulating effect, whereas others claim that S100 proteins inhibit the transcriptional activity of p53 (17–19, 21, 22). We previously showed that oligomerization of p53 weakens the binding to S100B and S100A4, and it was deduced that S100 proteins inhibit the oligomerization of p53, which causes the inhibitory effect on p53-mediated transcription (16, 20).

In this study, we analyzed the binding of five different S100 proteins to full-length p53 and also different oligomeric states of C-terminal fragments of p53 that consisted of the tetramerization (residues 325–355) and C-terminal domains (residues 360–393), some with mutations in the tetramerization domain that altered the oligomerization state. We used analytical size-exclusion chromatography (SEC), multiangle light scattering (MALS), and analytical ultracentrifugation (AUC) in vitro. We show that S100 family members differ in their ability to bind to the different oligomeric forms of p53. In addition, we found that some of the S100 proteins can bind p53 as a tetramer and identified the transactivation domain of p53 as another target site for S100 proteins. The in vitro data thus provide an explanation why S100 proteins have been found to activate as well as inhibit p53-mediated transcription.

MATERIALS AND METHODS

Plasmids, Protein Expression, and Purification—Plasmids used for the expression of S100A1, S100A2, S100A4, S100A6, and S100B and p53-(293–393) were as described (16, 20). pRSET plasmids of oligomerization-deficient mutants of p53-(293–393), respectively, p53-(293–393)-L344A and p53-(293–393)-L344P, were constructed by site-directed mutagenesis according to the QuikChange™ XL site-directed mutagenesis kit (Stratagene). The superstable full-length p53-variant (p53-QMFL) (23, 24) was expressed and purified as described previously (25, 26). The p53-QMFL with an additional tetracysteine

---

This article was selected as a Paper of the Week.

1 To whom correspondence should be addressed: MRC Centre for Protein Engineering, Hills Road, Cambridge CB2 0QH, United Kingdom. Tel.: 44-1223-402-136; Fax: 44-1223-402-104; E-mail: arf25@cam.ac.uk.

2 The abbreviations used are: SEC, size-exclusion chromatography; MALS, multiangle light scattering; AUC, analytical ultracentrifugation; QMFL, superstable full-length p53 variant; \(M_w\), weight average molar mass; \(M_n\), number average molar mass.
motif Cys-Cys-Pro-Gly-Cys at the C terminus (p53-QMF1-FlAsH) was purified similarly and specifically labeled with FlAsH-EDT2 (Invitrogen), which becomes fluorescent upon binding to the tetracycys motif.

**Analytical Size-exclusion Chromatography**—Analytical gel filtrations were performed using a GE Healthcare Superdex™ 75 analytical gel filtration column with a flow rate of 0.7 ml/min or a Superose™ 6 10/300GL column with a flow of 0.4 ml/min. The proteins were buffer-exchanged in physiological ionic strength buffer (25 mM Tris, pH 7.4, 10 mM CaCl₂, 99.2 mM NaCl, and 1 mM dithiothreitol), and 100 μl of protein sample at different concentrations were injected. For experiments with full-length p53, the proteins were changed into a buffer containing 20 mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol, 15 mM CaCl₂, and 1 mM dithiothreitol. To analyze the resulting peaks, we collected the eluted protein with a fraction collector, and the fractions were concentrated with a centrifugal filter and analyzed by SDS-PAGE. Alternatively, the SEC was coupled to a DAWN HELEOSTM MALS instrument (Wyatt Technology) and an Optilab™ rEX (Wyatt Technology). The on-line measurement of the intensity of the Rayleigh scattering as a function of the angle as well as the differential refractive index of the measurement system (28) (FDS, Aviv Biomedical, Lakewood, NJ) in SedVel60K-FDS fluorescence velocity cells (Spin Analytical, Inc., Durham, NH). The proteins were buffer-exchanged in physiological ionic strength buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol, 15 mM β-mercaptoethanol, 0.1% bovine serum albumin. The concentration of p53 was 250 nM with varying amounts of S100 protein were titrated at different t, from a SEC. The Mₘ determined by MALS correspond to a tetramer, dimer, and monomer for the three individual peaks.

**RESULTS**

**Oligomerization of p53-(293–393) Variants**—The state of oligomerization of a protein will depend on the ratio of its concentration to its dissociation constants. To study the binding to different oligomeric forms of the p53 C terminus, we expressed and purified: p53-(293–393) recombinant protein, which should be tetrameric under the experimental conditions; a mutant of weakened interface that should tend to be dimeric, p53-(293–393)-L344P (32). The oligomerization state of p53-(293–393) was monitored by analytical SEC combined with MALS detection. The p53 variants have a large fraction of intrinsically disordered structure (33) and do not elute like globular proteins in a SEC; hence the relative molecular weight and the oligomerization cannot be studied appropriately using globular protein standards. MALS is a powerful tool to characterize the Mₘ of compounds showing anomalous elution profiles in SEC (34). The three individual p53-(293–393) variants eluted with different retention times (tₑ) in SEC in separate runs. The calculated Mₘ of ~12, ~24, and ~46 kDa for the peaks in the elution profiles corresponded well to p53-(293–393) in different oligomeric states (Fig. 1 and Table 1).

**TABLE 1**

Size-exclusion chromatography of S100 proteins together with different p53(293–393) variants

| Protein | Mₘ [kDa] | WT | L344A | L344P |
|---------|---------|----|-------|-------|
| S100    | 45.8 ± 0.4 | 49.3 ± 2.8 | 45.2 ± 2.2 | 45.7 ± 0.9 |
| S100A1  | 21.2 ± 1.0 | 23.0 ± 1.7 | 23.7 ± 1.1 | 24.1 ± 0.6 |
| S100A2  | 22.8 ± 0.4 | 24.2 ± 1.8 | 24.4 ± 1.8 | 24.5 ± 0.8* |
| S100A4  | 45.7 ± 0.9 | 24.4 ± 1.8 | 24.5 ± 0.8* | 24.5 ± 0.8* |
| S100A5  | 20.5 ± 0.8 | 21.8 ± 0.2 | 21.8 ± 0.2 | 21.8 ± 0.2 |
| S100B   | 18.0 ± 0.6 | 18.0 ± 0.6 | 18.0 ± 0.6 | 18.0 ± 0.6 |

* S.E. of four measurements at different concentrations.

**RESULTS**

S100 Proteins Form a Complex with the Monomeric Fragment of p53—S100A1, S100A2, S100A4, S100A6, and S100B were expressed and purified. All S100 proteins eluted as dimers
In SEC-MALS elution profiles, the eluted peak with the highest S100A4 and S100A6 did not bind to the dimer of p53 (Table 1). S100B disrupted upon binding to S100B. In contrast, S100A1, S100A2, S100A4, and S100A6 did not form a complex with tetrameric p53-(293–393) with 150 μM S100B differed in t_r for the eluted peaks was observed (data not shown). For all S100 proteins, we did not detect additional peaks in the elution profiles, indicating a disruption of the p53 tetramer upon binding, not even after long incubation times of 48 h (data not shown).

S100B Binds to the Tetramer of p53-(293–393)—S100B bound to wild-type p53-(293–393) in SEC-MALS experiments (Table 1 and Fig. 3B). The t_r of the peak for p53-(293–393) shifted upon the addition of S100B. The M_w of ~80 kDa of the elution peak would correspond best to two dimers of S100 (~21 kDa) in a complex with a tetramer of p53 (~46 kDa). Under the same conditions, S100A1, S100A2, S100A4, and S100A6 did not form a complex with tetrameric p53-(293–393). The M_w of the dominating peak was ~46 kDa, corresponding to unbound tetrameric p53-(293–393) (Table 1). In addition, no shift in t_r for the eluted peaks was observed (data not shown). For all S100 proteins, we did not detect additional peaks in the elution profiles, indicating a disruption of the p53 tetramer upon binding, not even after long incubation times of 48 h (data not shown).

S100 Proteins Bind Both Monomeric and Tetrameric p53

S100 Proteins Form a Complex with the Tetramer of Full-length p53—The binding of S100 proteins to p53 was also studied by fluorescence analytical ultracentrifugation with a thermodynamically stabilized full-length p53-QMFL labeled with a FIAsh tag (26). The concentration of p53 in the experiments was 250 nM. Further, an excess of S100 protein was added to study the formation of complexes as well as a possible influence on p53 tetramerization (Fig. 4). The AUC of p53-QMFL–FIAsh gave two peaks, corresponding to a tetramer of p53 and lower oligomers. The calculated M_w of ~176 kDa for the p53-QMFL–FIAsh corresponded well with its theoretical M_w of ~176 kDa.
Upon the addition of S100 protein, an increase in the sedimentation coefficient (measured at the top of the peak) could be observed for the tetramer as well as for the lower oligomers of p53-QMFL-FlAsH. The increase in sedimentation coefficient indicated a bigger size of the molecule, corresponding to a complex formed between the labeled p53 and S100 protein. The addition of excess S100B resulted in a calculated $M_w$ of ~268 kDa for the complex using the same frictional coefficient as a fitting parameter as for p53-QMFL-FlAsH alone. The estimated mass would correspond to four dimers of S100B binding to a tetramer of p53. When the concentration of S100 was reduced from 10 to 1 $\mu$M, a smaller shift in sedimentation coefficient and increase in $M_w$ to ~199 kDa was detected, implying that the complex between S100B and the tetramer of p53 was weak. Further, no relative increase in the fluorescence signal for the lower oligomers when compared with the tetramer of QMFL-FlAsH could be detected. A change in the signal distribution would indicate a disruption of the p53-QMFL-FlAsH tetramer. Similar results were obtained for S100A2 and S100A6. In contrast, only a minor increase in the sedimentation coefficient and $M_w$ was detected for S100A1 and S100A4, implying a weaker interaction with p53-QMFL-FlAsH (Fig. 4).

To check the results, we performed analytical SEC with a Superose™ 6 column and injected p53-QMFL together with
S100 Proteins Bind Both Monomeric and Tetrameric p53

S100Proteins. The formation of a complex was monitored by SDS-PAGE analysis of the eluted peak. Upon the addition of S100B, S100A2, and S100A6, we saw a slight shift in the elution volume for the p53-QMFL peak (Fig. 5). SDS-PAGE analysis of the eluted peaks revealed a co-elution of S100 proteins with p53-QMFL (Fig. 5B). The band corresponding to S100 proteins was faint when compared with the band for p53, which supports the idea that the complex between the p53 tetramer and S100 proteins was weak. No additional peaks corresponding to a complex of S100 proteins and lower oligomers of p53-QMFL could be observed. In contrast, no co-elution of S100A1 and S100A4 with p53-QMFL could be detected by SDS-PAGE (Fig. 5).

**DISCUSSION**

We found that proteins of the S100 family bind tightly to the monomeric p53 fragment of residues 293–393 in a stoichiometry of one dimer of S100 binding per one p53 monomer. We discovered that a subset of S100 proteins can additionally bind tetrameric p53, and we noted that S100 proteins had different binding properties toward different oligomeric forms (Table 2). We also found a novel binding site common for all S100 proteins in the transactivation domain of p53 (1–57).

S100B and S100A2 bind tightly to the C-terminal domains of p53, residues 367–393, (16, 20). We found that these proteins were able to form a tight complex with a monomeric mutant of p53 (293–393), which was stable enough to be detected by SEC. No stable complex was observed with S100A4 and S100A6. This absence might have been a manifestation of their known weaker binding to p53 (16, 20) so that their complexes might not have been stable enough to remain intact during analytical gel filtration.

S100B was able to disrupt the dimeric mutant p53-(293–393)-L344A that has a weakened interface and bound p53 as a monomer. This confirmed that S100B is able to influence the oligomerization equilibrium of p53 as proposed previously (20). The equilibrium is shifted to the inactive monomer side; thus the tight binding of the monomer of p53 and the disruption of the dimer in vitro explain the inhibitory effect of S100B on p53 activity as reported previously in transcriptional activation assays (21). It is possible on molecular mass data alone that the peak of ~33 kDa is a monomer of S100B binding to a dimer of p53. However, the $K_d$ for S100B dimer-
S100 Proteins Bind Both Monomeric and Tetrameric p53

Figure 6. Binding of S100 proteins to the transactivation domain of p53. S100 proteins were titrated to 0.5 μM p53-(1–57)-Lys-methoxycoumarin in fluorescence anisotropy experiments.

S100 Proteins Bind Both Monomeric and Tetrameric p53

S100 proteins bind to the transactivation domain of p53. The binding is competitive with that of p53-(293–393), and our studies indicated that the monomer of p53 is the primary binding site. The binding affinity of S100 proteins to p53 is stronger than to other monomeric proteins, such as S100A1, S100A2, S100A4, and S100A6.

S100A1, S100A2, S100A4, and S100A6 did not disrupt the oligomerization of p53. These proteins also had weaker affinities for p53-(293–393) than S100B in fluorescence anisotropy experiments. S100B was found to bind to p53 as a tetramer with a weak affinity. This binding mode is supported by fluorescence anisotropy studies that showed an increasingly lower affinity when the concentration of p53 increased (that is, the lower the concentration, the higher the fraction of lower oligomers).

S100A2 and S100B also bind to the negative regulatory domain of p53-(367–393). Consequently, the binding of S100 proteins to the tetramer could result from the binding to the C terminus of p53. On the other hand, we found that S100A6 bound to the full-length tetramer of p53, although it does not bind to the negative regulatory domain. We found that the S100 proteins bound to the N-terminal transactivation domain of p53. The tight binding of S100 proteins was observed in previous pull-down studies, which has not been detected in previous pull-down studies.

S100A1, S100A2, S100A4, and S100A6 activated p53-mediated transcription. Activation of p53 cannot be explained by the previously reported influence of S100 on oligomerization of p53 in vitro but might be caused by binding of S100 proteins to the tetramer of p53. The binding to the tetramer could have a stabilizing effect or protect p53 from degradation.

Different S100 proteins bind p53 in different ways (Table 2). For example, only S100B is able to disrupt the dimer of p53. S100A1 is able to bind tightly to the monomer of p53 but not to the tetramer, whereas only binding to the tetramer but not to the monomer could be detected for S100A6.

Based on the finding that proteins of the S100 family bind p53 as a monomer as well as a tetramer, we propose a model for the regulatory effect of S100 proteins on p53 where S100 can bind the monomer of p53 and inhibit its activity as well as to the tetramer with an activating effect (Fig. 7A). The model implies that the regulation of p53 activity by S100 proteins is complex and depends on: 1) the concentration of Ca²⁺ to induce binding to p53; 2) the particular S100 protein because all the S100 proteins have different affinities for the monomer and the tetramer of p53; and 3) the concentration of p53 and the equilibrium and the exchange rates between its oligomers. When the concentration of p53 is lower than the K₅₅ of ~120 nM (26), as in for example unstressed cells (1–10 nM) (37), the monomer, dimer, and tetramer forms of p53 are present within the cell, and S100 is able to bind the monomer and significantly shift the oligomerization equilibrium toward the inactive form (Fig. 7C). In stressed cells, the concentration of p53 increases 5–1000-fold and consequently is within the range of the K₅₅ for tetramerization or even higher. At concentrations much higher than the K₅₅, practically all of p53 is tetrameric, and S100 will mainly bind to the tetramer (Fig. 7E).
S100 Proteins Bind Both Monomeric and Tetrameric p53

FIGURE 7. Binding model of S100 and p53. A, proteins of the S100 family can bind p53 as a tetramer as well as a monomer. The different oligomeric forms of p53 are in equilibrium. S100 can have an activating function binding to the tetramer or an inhibiting effect binding to the monomer of p53. B, at low concentrations of p53 (below the \( K_d \) for tetramerization), there is a significant equilibrium between tetramer, dimer, and monomer of p53. C, the tight binding of S100 to the monomer will displace the oligomerization equilibrium (illustrated by the different lengths of the equilibrium arrows) in favor of the monomer and consequently inhibit p53 function. D, when the concentration of p53 is much higher than the \( K_d \) for tetramerization, almost all of p53 is present as a tetramer. E, under these circumstances, the tight binding of S100 to the p53 monomer will not significantly alter the tetramerization equilibrium, and the inhibiting effect is overwhelmed by the activating or stabilizing effect of S100 binding to the tetramer of p53.

The dual function of S100 could explain contradictory results about the influence of S100 proteins on p53. S100B was shown to have an inhibitory effect in one study (21), but in other studies, it was proposed to stimulate p53 activity (22, 36). S100A2 activates p53-mediated transcription, but the positive effect disappears when more DNA encoding S100A2 is transfected (17). According to our model, the two S100 proteins bind both the tetramer and the monomer of p53. Consequently, the results of in vivo studies might differ depending on the expression level of the proteins. S100A6 activates p53 (18), and according to our model, S100A6 binds to the tetramer of p53 but only weakly to the monomer of p53 when compared with the other S100 proteins.

Finally, the proposed model suggests that S100 proteins contribute to the fine regulation of p53 activity. In unstressed cells, the concentration of p53 is kept very low; thus a relatively high amount will be in the form of a monomer, which binds tightly to S100 proteins. Binding of S100 to p53 in low concentrations could therefore help to reduce any basal activity. On the other hand, at high concentrations of p53, S100 proteins can further stimulate its transcriptional activity by binding to the tetramer.

Acknowledgments—We thank Dr. C. M. Johnson for help with the experimental setup of SEC-MALS and critical reading of the manuscript and Caroline Blair for help with protein expression and purification.

REFERENCES

1. Donato, R. (2003) Microsc. Res. Tech. 60, 540–551
2. Moore, B. W. (1965) Biochem. Biophys. Res. Commun. 19, 739–744
3. Koch, M., Bhattacharya, S., Kehl, T., Gimona, M., Vasak, M., Chazin, W., Heizmann, C. W., Kroneck, P. M., and Fritz, G. (2007) Biochim. Biophys. Acta 1773, 457–470
4. Ostendorp, T., Leclerc, E., Galichet, A., Koch, M., Demling, N., Weigle, B., Heizmann, C. W., Kroneck, P. M., and Fritz, G. (2007) EMBO J. 26, 3868–3878
5. Donato, R. (2001) Int. J. Biochem. Cell Biol. 33, 637–668
6. Hiratsuka, S., Watanabe, A., Aburatani, H., and Maru, Y. (2006) Nat. Cell Biol. 8, 1369–1375
7. Kriajevska, M., Bronstein, I. B., Scott, D. J., Tarabykina, S., Fischer-Larsen, M., Issinger, O., and Lukandin, E. (2000) Biochim. Biophys. Acta 1498, 252–263
8. Salama, I., Malone, P. S., Mihameed, F., and Jones, J. L. (2008) Eur. J. Surg. Oncol. 34, 357–364
9. Davies, M. P., Rudland, P. S., Robertson, L., Parry, E. W., Jolicoeur, P., and Barrail, R. (1996) Oncogene 13, 1631–1637
10. Levine, A. J. (1997) Cell 88, 323–331
11. Vousden, K. H. (2000) Cell 103, 691–694
12. Appella, E., and Anderson, C. W. (2000) Pathol. Biol. (Paris) 48, 227–245
13. Braithwaite, A. W., Del Sal, W., and Lu, X. (2006) Cell Death Differ. 13, 984–993
14. Lavin, M. F., and Gueven, N. (2006) Cell Death Differ. 13, 941–950
15. Baudier, J., Delphin, C., Grunwald, D., Khochbin, S., and Lawrence, J. J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11627–11631
16. Fernandez-Fernandez, M. R., Rutherford, T. J., and Fersht, A. R. (2008) Protein Sci. 17, 1663–1670
17. Mueller, A., Schafer, B. W., Ferrari, S., Weibel, M., Makek, M., Hochli, M., and Heizmann, C. W. (2005) J. Biol. Chem. 280, 29186–29193
18. Slomnicki, L. P., Nawrot, B., and Léonard, W. (2008) Int. J. Biochem. Cell Biol. 40, 784–790
19. Grigorian, M., Andresen, S., Tulchinsky, E., Kriajevska, M., Carlberg, C., Kruse, C., Cohn, M., Ambartsouman, N., Christensen, A., Selivanova, G., and Lukandin, E. (2001) J. Biol. Chem. 276, 22699–22708
20. Fernandez-Fernandez, M. R., Veprintsev, D. B., and Fersht, A. R. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 4735–4740
21. Lin, J., Blake, M., Tang, C., Zimmer, D., Rustandi, R. R., Weber, D. J., and Carrier, F. (2001) J. Biol. Chem. 276, 35037–35041
22. Scotto, C., Delphin, C., Deloulme, J. C., and Baudier, J. (1999) Mol. Cell. Biol. 19, 7168–7180
23. Joerger, A. C., Allen, M. D., and Fersht, A. R. (2004) J. Biol. Chem. 279, 1291–1296
24. Nikolova, P. V., Henckel, J., Lane, D. P., and Fersht, A. R. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 14675–14680
25. Ang, H. C., Joerger, A. C., Mayer, S., and Fersht, A. R. (2006) J. Biol. Chem. 281, 21934–21941
26. Rajagopalan, S., Jaulet, A. M., Wells, M., Veprintsev, D. B., and Fersht, A. R. (2008) Nucleic Acids Res. 36, 5983–5991
27. Trathnigg, B. (1995) Prog. Polym. Sci. 20, 615–650
28. MacGregor, I. K., Anderson, A. L., and Laue, T. M. (2004) Biophys. Chem. 108, 165–185
29. Schuck, P. (2000) Biophys. J. 78, 1606–1619
30. Teufel, D. P., Freund, S. M., Bycroft, M., and Fersht, A. R. (2007) Proc. Natl. Acad. Sci. U. S. A. 104, 7009–7014
31. Lomax, M. E., Barnes, D. M., Hupp, T. R., Pucksley, S. M., and Camplejohn, R. S. (1998) Oncogene 17, 643–649
32. Mateu, M. G., and Fersht, A. R. (1998) EMBO J. 17, 2748–2758
33. Bell, S., Klein, C., Muller, L., Hansen, S., and Buchner, J. (2002) J. Mol. Biol. 322, 917–927
34. Kim, C., Morel, M. H., Beuve, J. S., Guilbert, S., Collet, A., and Bonfils, F. (2008) J. Chromatogr. A 1213, 181–188
35. Drohat, A. C., Nenortas, E., Beckett, D., and Weber, D. J. (1997) Protein Sci. 6, 1577–1582
36. Scotto, C., Deloulme, J. C., Rousseau, D., Chambaz, E., and Baudier, J. (1998) Mol. Cell. Biol. 18, 4272–4281
37. Chene, P. (2001) Curr. Med. Chem. Anti-cancer Agents 1, 151–161